These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases. Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501 [TBL] [Abstract][Full Text] [Related]
8. Single chromosomal abnormalities in Philadelphia-negative chronic myeloproliferative disorders. Panani AD In Vivo; 2007; 21(5):867-70. PubMed ID: 18019426 [TBL] [Abstract][Full Text] [Related]
9. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers. Hussein K; Bock O; Kreipe H Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878 [TBL] [Abstract][Full Text] [Related]
11. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression. Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343 [TBL] [Abstract][Full Text] [Related]
12. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Tefferi A; Thiele J; Vardiman JW Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396 [TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648 [TBL] [Abstract][Full Text] [Related]
14. Breakpoint cluster region, immunoglobulin, and T-cell receptor gene rearrangement analysis in juvenile chronic myelogenous leukemia. Farhi DC; Luckey CN; Siddiqui AM Mod Pathol; 1995 May; 8(4):389-93. PubMed ID: 7567936 [TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of insulin-like growth factor-2 (IGF-2) in Philadelphia chromosome negative chronic myeloproliferative disorders. Bock O; Tessema M; Serinsöz E; von Wasielewski R; Büsche G; Kreipe H Leuk Res; 2004 Nov; 28(11):1145-51. PubMed ID: 15380337 [TBL] [Abstract][Full Text] [Related]
16. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. Orazi A Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881 [TBL] [Abstract][Full Text] [Related]
17. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions. Douet-Guilbert N; Basinko A; Morel F; Le Bris MJ; Ugo V; Morice P; Berthou C; De Braekeleer M Ann Hematol; 2008 Jul; 87(7):537-44. PubMed ID: 18350294 [TBL] [Abstract][Full Text] [Related]